News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
332,732 Results
Type
Article (19974)
Company Profile (128)
Press Release (312630)
Section
Business (105378)
Career Advice (879)
Deals (18534)
Drug Delivery (97)
Drug Development (50772)
Employer Resources (79)
FDA (7684)
Job Trends (7742)
News (185865)
Policy (17330)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (5)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (3)
2024 Genetown Standard (4)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 BioForest Digital (4)
2025 Lone Star Bio Digital (4)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Pharm Country Standard (1)
Academia (733)
Accelerated approval (1)
Adcomms (17)
Allergies (40)
Alliances (27827)
ALS (52)
Alzheimer's disease (623)
Antibody-drug conjugate (ADC) (86)
Approvals (7697)
Artificial intelligence (131)
Autoimmune disease (11)
Automation (4)
Bankruptcy (177)
Best Places to Work (5553)
BIOSECURE Act (13)
Biosimilars (93)
Biotechnology (57)
Bladder cancer (29)
Brain cancer (18)
Breast cancer (102)
Cancer (990)
Cardiovascular disease (99)
Career advice (711)
Career pathing (20)
CAR-T (53)
Cell therapy (145)
Cervical cancer (5)
Clinical research (42567)
Collaboration (439)
Compensation (146)
Complete response letters (22)
COVID-19 (1097)
CRISPR (21)
C-suite (135)
Cystic fibrosis (56)
Data (1026)
Decentralized trials (2)
Denatured (18)
Depression (23)
Diabetes (133)
Diagnostics (1806)
Digital health (5)
Diversity (7)
Diversity, equity & inclusion (21)
Drug discovery (72)
Drug pricing (108)
Drug shortages (30)
Duchenne muscular dystrophy (56)
Earnings (38932)
Editorial (29)
Employer branding (10)
Employer resources (73)
Events (48448)
Executive appointments (406)
FDA (8224)
Featured Employer (23)
Friedreich's ataxia (3)
Frontotemporal dementia (1)
Funding (297)
Gene editing (45)
Generative AI (17)
Gene therapy (139)
GLP-1 (571)
Government (1831)
Grass and pollen (2)
Guidances (18)
Healthcare (5902)
Huntington's disease (13)
IgA nephropathy (18)
Immunology and inflammation (76)
Indications (17)
Infectious disease (1173)
Inflammatory bowel disease (82)
Inflation Reduction Act (8)
Influenza (22)
Intellectual property (51)
Interviews (116)
IPO (7366)
IRA (45)
Job creations (2432)
Job search strategy (648)
Kidney cancer (7)
Labor market (21)
Layoffs (272)
Leadership (13)
Legal (4113)
Liver cancer (31)
Lung cancer (149)
Lymphoma (81)
Machine learning (2)
Management (30)
Manufacturing (187)
MASH (45)
Medical device (1960)
Medtech (1963)
Mergers & acquisitions (11400)
Metabolic disorders (466)
Multiple sclerosis (44)
NASH (20)
Neurodegenerative disease (43)
Neuropsychiatric disorders (20)
Neuroscience (904)
NextGen: Class of 2025 (2357)
Non-profit (906)
Northern California (1010)
Now hiring (20)
Obesity (293)
Opinion (189)
Ovarian cancer (33)
Pain (63)
Pancreatic cancer (35)
Parkinson's disease (77)
Partnered (9)
Patents (128)
Patient recruitment (45)
Peanut (16)
People (33368)
Pharmaceutical (74)
Pharmacy benefit managers (21)
Phase I (13325)
Phase II (18009)
Phase III (14467)
Pipeline (618)
Podcasts (68)
Policy (101)
Postmarket research (1618)
Preclinical (4643)
Press Release (29)
Prostate cancer (57)
Psychedelics (16)
Radiopharmaceuticals (160)
Rare diseases (228)
Real estate (3170)
Recruiting (29)
Regulatory (12476)
Reports (22)
Research institute (817)
Resumes & cover letters (138)
Rett syndrome (1)
RNA editing (1)
RSV (23)
Schizophrenia (55)
Series A (55)
Series B (31)
Service/supplier (6)
Sickle cell disease (34)
Southern California (972)
Special edition (15)
Spinal muscular atrophy (111)
Sponsored (12)
Startups (2008)
State (2)
Stomach cancer (9)
Supply chain (49)
The Weekly (47)
United States (9525)
Vaccines (263)
Venture capitalists (27)
Webinars (11)
Weight loss (233)
Women's health (14)
Worklife (7)
Date
Today (76)
Last 7 days (304)
Last 30 days (1392)
Last 365 days (17032)
2025 (3990)
2024 (17669)
2023 (19637)
2022 (25865)
2021 (26639)
2020 (24870)
2019 (20057)
2018 (15587)
2017 (17253)
2016 (16202)
2015 (18801)
2014 (14787)
2013 (12552)
2012 (13482)
2011 (13817)
2010 (12738)
Location
Africa (408)
Alabama (22)
Alaska (1)
Arizona (63)
Arkansas (8)
Asia (24840)
Australia (3208)
California (2373)
Canada (1057)
China (307)
Colorado (94)
Connecticut (96)
Delaware (66)
Europe (51255)
Florida (408)
Georgia (51)
Idaho (16)
Illinois (232)
India (18)
Indiana (167)
Iowa (3)
Japan (108)
Kansas (60)
Kentucky (17)
Louisiana (1)
Maine (4)
Maryland (353)
Massachusetts (1992)
Michigan (45)
Minnesota (130)
Mississippi (1)
Missouri (26)
Montana (10)
Nebraska (11)
Nevada (15)
New Hampshire (8)
New Jersey (959)
New Mexico (21)
New York (690)
North Carolina (479)
North Dakota (2)
Northern California (1010)
Ohio (80)
Oklahoma (5)
Oregon (21)
Pennsylvania (557)
Puerto Rico (10)
Rhode Island (13)
South America (606)
South Carolina (3)
Southern California (972)
Tennessee (38)
Texas (317)
Utah (53)
Virginia (78)
Washington D.C. (41)
Washington State (203)
Wisconsin (19)
332,732 Results for "ascentage pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Ascentage Pharma Reports Full Year 2024 Unaudited Financial Results and Business Updates
March 28, 2025
·
20 min read
Press Releases
Ascentage Pharma to Report Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025
March 12, 2025
·
1 min read
Press Releases
Ascentage Pharma to Present Five Preclinical Studies from Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2025
March 26, 2025
·
7 min read
Press Releases
Ascentage Pharma Announces Closing of U.S. Initial Public Offering
January 28, 2025
·
1 min read
Press Releases
Ascentage Pharma Announces Pricing of U.S. Initial Public Offering
January 23, 2025
·
2 min read
Press Releases
Ascentage Pharma Announces Partial Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares
February 7, 2025
·
1 min read
IPO
Chinese Biotech Ascentage Aims For $134M IPO
Ascentage is looking to use the IPO proceeds to advance its Phase III candidates for chronic or small lymphocytic leukemia and for certain types of chronic myeloid leukemia.
January 22, 2025
·
2 min read
·
Tristan Manalac
BioCapital
Ascentage Pharma Announces Closing of US$75 Million Equity Investment by Takeda
Ascentage Pharma, a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B, and age-related diseases, announced that the agreed equity investment by Takeda has been closed on June 20, 2024, with all proceeds already received.
June 20, 2024
·
3 min read
Business
Ascentage Pharma Announces 2023 Annual Results
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its annual results for the full year 2023.
March 27, 2024
·
10 min read
Deals
Ascentage Pharma Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering of American Depositary Shares
Ascentage Pharma announced that it has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission relating to the proposed initial public offering of American depositary shares representing its ordinary shares.
June 23, 2024
·
1 min read
1 of 33,274
Next
